ImmunityBio, Inc. IBRX Accrued preclinical and clinical trial costs
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:AccruedPreclinicalAndClinicalTrialCosts.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s accrued preclinical and clinical trial costs.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s accrued preclinical and clinical trial costs?
- ImmunityBio, Inc. (IBRX) reported accrued preclinical and clinical trial costs of $10.26M in Q1 2026.
- How has ImmunityBio, Inc.'s accrued preclinical and clinical trial costs changed year-over-year?
- ImmunityBio, Inc.'s accrued preclinical and clinical trial costs increased by 225.4% year-over-year, from $3.15M to $10.26M.
- What is the long-term trend for ImmunityBio, Inc.'s accrued preclinical and clinical trial costs?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s accrued preclinical and clinical trial costs has grown at a 4.8% compound annual growth rate (CAGR), from $4.34M to $5.49M.